Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have demonstrated that doxycycline, a commonly available and inexpensive antibiotic, can improve survival rates and neurological outcomes in Central Nervous System Tuberculosis (CNS-TB) in a preclinical non-human study.